AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04804072 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Testing and referral for vaccination or treatment for hepatitis A virus (HAV) and hepatitis B virus (HBV)
Description: Testing and referral for vaccination or treatment for HAV and HBV
Study NCT04804072 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Testing and referral for treatment for hepatitis C virus (HCV)
Description: Testing and referral for treatment for HCV
Study NCT06270797 — intervention group
Intervention type: PROCEDURE
Intervention: intubation for general anesthesia
Description: routine intubation for general anesthesia
Study NCT06282172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with BTL-785-7
Description: Treatment with BTL-785-7 delivering simultaneously radiofrequency (RF) and HIFES energy on the submental area
Study NCT04950985 — intervention group
Intervention type: OTHER
Intervention: Observational Study
Description: Observational study
Study NCT04959019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised combined endurance and resistance training (CERT)
Description: Subjects will undergo up to 18 supervised sessions of a structured exercise program of combined endurance and resistance training (CERT). Supervised CERT will occur for 3 days/week, approx. 1 hr per session. Endurance training will start at 15 minutes and progress to 30 minutes of cycling on a stationary recumbent bicycle at 65-85% of heart rate reserve by week 3. Resistance training volume and intensity (baseline determined from strength tests) will progress over the first four sessions to 3 sets of 8-12 repetitions to volitional fatigue for 8 movements, with alternating upper-body and lower-body movements during the session. Progression will be incorporated throughout the trial for both endurance and resistance training to maintain relative intensity.
Study NCT04959019 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Delayed supervised combined endurance and resistance training (CERT)
Description: After a 6-week delay period (no-exercise control), subjects will undergo up to 18 supervised sessions of a structured exercise program of combined endurance and resistance training (CERT). Supervised CERT will occur for 3 days/week, approx. 1 hr per session. Endurance training will start at 15 minutes and progress to 30 minutes of cycling on a stationary recumbent bicycle at 65-85% of heart rate reserve by week 3. Resistance training volume and intensity (baseline determined from strength tests) will progress over the first four sessions to 3 sets of 8-12 repetitions to volitional fatigue for 8 movements, with alternating upper-body and lower-body movements during the session. Progression will be incorporated throughout the trial for both endurance and resistance training to maintain relative intensity.
Study NCT04804072 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Testing and referral for treatment for hepatitis C virus (HCV)
Description: Testing and referral for treatment for HCV
Study NCT04804072 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sexually transmitted infection (STI) testing and treatment
Description: STI testing and treatment
Study NCT04804072 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sexually transmitted infection (STI) testing and treatment
Description: STI testing and treatment
Study NCT04804072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary care
Description: Primary care
Study NCT04804072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Harm reduction services
Description: Harm reduction services
Study NCT04804072 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Harm reduction services
Description: Harm reduction services
Study NCT04804072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer navigation
Description: Peer navigation
Study NCT04804072 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer navigation
Description: Peer navigation
Study NCT04804072 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COVID-19 testing and referral for further evaluation, care and/or treatment
Description: COVID-19 testing and referral for further evaluation, care and/or treatment
Study NCT04804072 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 testing and referral for further evaluation, care and/or treatment
Description: COVID-19 testing and referral for further evaluation, care and/or treatment
Study NCT06779968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femoral Nerve Block
Description: In the femoral nerve block (FNB) group, the femoral nerve was blocked distal to the inguinal ligament and lateral to the femoral artery. Under sterile conditions and ultrasound guidance using a short-axis out-of-plane approach, a 22-gauge insulated needle was advanced adjacent to the femoral nerve. Following confirmation of correct needle tip placement, a 20 mL volume of either 266 mg liposomal bupivacaine (diluted as indicated) or 0.2% ropivacaine was injected. This was followed by a continuous infusion at a rate of 5-10 mL/hr. For pediatric patients, a continuous infusion of 0.2% ropivacaine was administered at an initial bolus of 0.2-0.5 mg/kg, followed by a continuous infusion of 0.1-0.3 mg/kg/hr.
Study NCT06779968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined Sciatic and Femoral Nerve Block
Description: In the combined sciatic and femoral nerve block (CS-FNB) group, the femoral nerve block was performed as described above. The sciatic nerve block was performed at either the gluteal region or popliteal fossa. Under sterile conditions and ultrasound guidance using either an in-plane or out-of-plane approach, a 22-gauge insulated needle was advanced adjacent to the sciatic nerve. Following confirmation of correct needle tip placement, a 20 mL volume of either 266 mg liposomal bupivacaine (diluted as indicated) or 0.2% ropivacaine was injected. This was followed by a continuous infusion at a rate of 5-10 mL/hr. For pediatric patients, a continuous infusion of 0.2% ropivacaine was administered at an initial bolus of 0.2-0.5 mg/kg, followed by a continuous infusion of 0.1-0.3 mg/kg/hr.
Study NCT06779968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumbar plexus block
Description: In the lumbar plexus block (LPB) group, the lumbar plexus was blocked paraspinally within the psoas muscle. Under sterile conditions, ultrasound guidance, or with the assistance of a nerve stimulator, using either an in-plane or out-of-plane approach, a 22-gauge insulated needle was advanced within the psoas muscle adjacent to the lumbar plexus. Following confirmation of correct needle tip placement, a 20 mL volume of either 266 mg liposomal bupivacaine (diluted as indicated) or 0.2% ropivacaine was injected. This was followed by a continuous infusion at a rate of 5-10 mL/hr. For pediatric patients, a continuous infusion of 0.2% ropivacaine was administered at an initial bolus of 0.2-0.5 mg/kg, followed by a continuous infusion of 0.1-0.3 mg/kg/hr.
Study NCT06779968 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Analgesia
Description: For epidural analgesia, an initial bolus of 5-15 mL of 0.5% ropivacaine was administered followed by a continuous infusion of 0.2% ropivacaine at a rate of 3-10 mL/hr. For pediatric patients, an initial bolus of 0.2% ropivacaine at 0.5-1 mg/kg was administered, not exceeding a maximum total dose of 2-2.5 mg/kg, followed by a continuous infusion of 0.1-0.3 mg/kg/hr.
Study NCT06779968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous patient-controlled analgesia
Description: For intravenous patient-controlled analgesia (PCA), fentanyl was administered at a dose of 2 mcg/kg, diluted in 100 mL of normal saline. The basal infusion rate was set at 2 mL/hr, with a PCA dose of 2 mL and a lockout interval of 15 minutes.
Study NCT06779968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: General Aneasthesia
Description: Following administration of the regional anesthesia, general anesthesia with endotracheal intubation will be performed. Anesthesia induction will be achieved using propofol (1.5-2 mg/kg i.v.), rocuronium (1-2 mg/kg i.v.), and fentanyl (1-2 μg/kg i.v.). Anesthesia will be maintained using sevoflurane or desflurane, with inhaled concentration adjusted based on Bispectral Index (BIS) monitoring. A continuous infusion of remifentanil (0.05-0.2 μg/kg/min) will be administered, with adjustments to maintain blood pressure and heart rate within ±20% of baseline values. Following induction, patients will be mechanically ventilated in pressure-regulated volume control (PRVC) mode. The ventilator (Aestiva; GE Healthcare, Waukesha, Wisconsin, USA) settings will be: tidal volume 6-8 mL/kg, positive end-expiratory pressure 0 cm H2O, inspiratory to expiratory ratio 1:2, respiratory rate 16 breaths per minute (BPM), and fraction of inspired oxygen 41%.
Study NCT04830397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS-101
Description: Ophthalmic solution 1x daily
Study NCT04830397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate
Description: Ophthalmic solution 1x daily
Study NCT05208281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNR-055 1.0-2.0-3.0 mg/kg
Description: Weekly IV infusion (lyophilized powder) 1.0-2.0-3.0 mg/kg
Study NCT05208281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNR-055 2.0 mg/kg
Description: Weekly IV infusion (lyophilized powder) 2.0 mg/kg
Study NCT05208281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNR-055 3.0 mg/kg
Description: Weekly IV infusion (lyophilized powder) 3.0 mg/kg
Study NCT04731103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abacavir (ABC)
Description: Tablets or oral solution
Study NCT04731103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine (3TC)
Description: Tablet or oral solution
Study NCT04731103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT)
Description: Tablet or oral solution
Study NCT06144645 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tVNS, intermittent stimulation
Description: transcutaneous vagus nerve stimulation, intermittent stimulation
Study NCT06144645 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tVNS, continuous stimulation
Description: transcutaneous vagus nerve stimulation, continuous stimulation
Study NCT06305598 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06305598 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT06305598 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT06305598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given SC
Study NCT06613984 — intervention group
Intervention type: BIOLOGICAL
Intervention: Bretovameran
Description: Comirnaty Injection (Bretovameran) is administered intramuscularly as a single dose of 0.3 mL for individuals 12 years of age and older regardless of prior COVID-19 vaccination status.
Study NCT06613139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHP2305
Description: Test drug: YHP2305 Comparator: YHR2404
Study NCT06613139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR2404
Description: Test drug: YHP2305 comparator: YHR2404
Study NCT06611813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy in Combination with Toripalimab
Description: Epirubicin (or Liposomal Doxorubicin)+Cyclophosphamide, intravenous infusion of 100 mg/m2. Epirubicin (or 35 mg/m2 liposomal doxorubicin)+600 mg/m2 cyclophosphamide, starting from the first day of the week, for a total of 12 weeks. Paclitaxel, administered intravenously at a dose of 260 mg/m2 every 3 weeks for a total of 12 weeks. During neoadjuvant chemotherapy and postoperative adjuvant therapy, use of Toripalimab: intravenous infusion of 240 mg, once every 3 weeks, combined with preoperative neoadjuvant and postoperative adjuvant therapy for a total of 1 year.
Study NCT05854563 — intervention group
Intervention type: OTHER
Intervention: Observational only, all subjects; measure DNA mutation and proteomic survey.
Description: Observational only, all subjects; measure DNA mutation and proteomic survey.
Study NCT06611813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR+ HER2 breast cancer
Description: During neoadjuvant chemotherapy and postoperative adjuvant therapy, use of Toripalimab: intravenous infusion of 240 mg, once every 3 weeks, combined with preoperative neoadjuvant therapy and postoperative adjuvant therapy for a total of 1 year.
Study NCT06673797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effects of Swiss Ball exercises
Description: Effects of Swiss ball exercises along with stretching as baseline treatment.~1. Stretching of hamstrings, calf, and quads for 10 seconds hold 5 times.~2. Swiss ball exercises. a.Sitting on the Swiss ball with the trunk straight, arms by the sides, and eyes opened progressed towards eyes closed for 10 seconds, then rest. b.Sitting on the Swiss ball with trunk straight and arm by the sides. The therapist would assist the patient to engage the patient in shifting the body's weight to one side and the other side sideways as well as anterior and posterior and up and down alternatively. Start with 10 repetitions. c. Standing with gym ball in front. The therapist would stand behind the patient to provide support and ask the patient to lean forward on the gym ball with both hands via outstretched arms. Start with 10 repetitions d. One leg weight bearing on a gym ball with the therapist behind the patient, gripping the patient's pelvis to provide support. Start with 10 repetitions
Study NCT06673797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EFFECTS OF FRENKEL EXERCISES ON STATIC AND DYNAMIC BALANCE IN ATAXIC CHILDREN WITH CEREBRAL PALSY
Description: Frenkel Exercises along with stretching as baseline treatment. The second intervention group would participate in Frenkel Exercises along with stretching as baseline treatment. The exercises would be performed 3 times per week for four weeks.~1. Stretching of hamstrings, calf, and quads for 10 seconds hold 5 times. (11)~   a. Calf stretching. b. Hamstring stretches. c. Quads stretching~2. Frenkel\&#39;s lower limb exercises are the exercises listed below. The time of each session was set to be 10 minutes in the first week and then raised by 5 minutes every week. The patients were given 5 minutes to relax after 10 minutes of practice. (12)~   1. Supine lying~  2. While sitting~  3. Stride standing
Study NCT06678984 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: with treated umbilical vein allograft
Description: Surgical treatment of female stress urinary incontinence using a treated allogeneic umbilical vein sling
Study NCT06678984 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: with autologous fascial pubovaginal sling
Description: Surgical treatment of female stress urinary incontinence using a autologous fascial pubovaginal sling
Study NCT06674668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulation
Description: The intervention includes traditional physiotherapy and 20 minutes of vibrotactile device use. As traditional physiotherapy, 30 seconds of 8 repetitions of passive wrist stretching exercises, radial head mobilization and deep friction massage will be applied to the affected extremity. Afterwards, the Intellinetix Elbow Wearable Vibration Device providing vibration will be worn on the affected tissue. The patient will remain in a comfortable position on the treatment table with the affected extremity for 20 minutes (10 minutes × 2).
Study NCT06674668 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physiotherapy
Description: For traditional physiotherapy, passive stretching exercises, radial head mobilization and deep friction massage will be applied to the affected extremity. Stretching exercises will be performed on the wrist flexor and extensor muscles for 30 seconds and 8 repetitions. Mill's manipulation, described by James Cyriax, will be applied once for radial head mobilization. The treatment will be completed with a 5-minute deep friction massage, affecting the wrist extensor muscle tendons and their ending points.
Study NCT06088563 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine injection
Description: Injection of the vaccine in renal transplant patients.
Study NCT06132828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR30206
Description: Subjects receive DR30206 intravenously
Study NCT05262959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib, PD-1
Description: Eligible subjects will receive Donafenib combined with PD-1 and TACE. Donafenib will be taken orally twice a day, 0.1mg each time.PD-1 will be used intravenously every 3 weeks.
Study NCT05262959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE will be performed by the investigator based on the patient's tumor status.
Study NCT05950139 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide vaccine
Description: Peptide vaccine
Study NCT04428437 — intervention group
Intervention type: DRUG
Intervention: Lenvatinib
Description: Prescribed by physician.
Study NCT06379425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Will add additional medications celecoxib and gabapentin to acetaminophen preoperatively prior to patient surgery
Study NCT06379425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Will add additional medications celecoxib and gabapentin to acetaminophen preoperatively prior to patient surgery
Study NCT06379425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Will add additional medications celecoxib and gabapentin to acetaminophen preoperatively prior to patient surgery
Study NCT06379425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Will add additional medications celecoxib and gabapentin to acetaminophen preoperatively prior to patient surgery
Study NCT05368077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Description: Adenotonsillectomy is a standard surgical procedure for pediatric OSA treatment, which involves removal of hypertrophied tonsils and adenoids.
Study NCT06233760 — intervention group
Intervention type: OTHER
Intervention: Rheumatic diseases Mistreatment Scale (RDMS)
Description: In 2012 Giraldo-Rodríguez developed and validated the Geriatric Mistreatment Scale (GAS), prior to its application, translation, cultural adaptation, and validation were performed.
Study NCT06233760 — intervention group
Intervention type: OTHER
Intervention: Health Assessment Questionnaire (HAQ)
Description: The HAQ is based on five patient-centered dimensions: disability, pain, medication effects, costs of care, and mortality
Study NCT06305598 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06305598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT06305598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Cypionate
Description: Given IM
Study NCT06404931 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal hysterectomy plus matrix reinforcement and sacrospinous fixation with Anchorsure® device
Description: Vaginal hysterectomy plus matrix reinforcement and sacrospinous fixation with Anchorsure® device
Study NCT06404931 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Vaginal hysterectomy plus anterior colporrhaphy
Description: Vaginal hysterectomy plus anterior colporrhaphy
Study NCT06404931 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Vaginal hysterectomy plus sacrospinous fixation with Anchorsure® device
Description: Vaginal hysterectomy plus sacrospinous fixation with Anchorsure® device
Study NCT06691503 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mediastinoscopic-assisted transhiatal laparoscopic esophagectomy (MATLE)
Description: mediastinoscopic-assisted transhiatal laparoscopic esophagectomy (MATLE)
Study NCT04347161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conversational Agent/Chatbot
Description: Via text messages, the bidirectional, conversation agent provides specific dosing instructions and motivational reminders to promote oral targeted therapy adherence and symptom management. Patients can report symptoms at any time via text message and are also prompted to report symptoms and medication adherence at periodic intervals. Reported symptoms are monitored and managed algorithmically according severity. High-grade symptoms are triaged directly to the patients' cancer care team. Patients in the intervention arm will use MEMS caps to enable capture of the primary outcome and asked to complete longitudinal surveys.
Study NCT04347161 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients in the control arm will receive usual care, which includes receiving information about dosing and self-administration of oral therapy, and anticipatory guidance for patients regarding management of side effects. Patients in the control arm will use MEMS caps to enable capture of the primary outcome and asked to complete longitudinal surveys.
Study NCT06688487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early extubation of hypoxemic patients
Description: patient extubated after the spontaneous ventilation trial despite the presence of hypoxemia defined by SpO2 ≤ 90% either in T-piece under 6 L/min, or under FiO2 = 40% if SBT is performed in spontaneous ventilation with minimal inspiratory assistance.
Study NCT06297265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lymphedema Management
Description: Undergo MLD breast massage